KASL clinical practice guidelines: management of hepatitis C

The Korean Association for the Study of the Liver (KASL) Practice Guidelines for Management of Hepatitis C were first established in 2004, and revised in 2013, when direct-acting antivirals (DAA) were not approved in Korea. Since then, numerous studies of the efficacy, adverse effects and drug-drug interactions (DDI) of interferon-free DAA combination therapy have been published. With all oral DAA therapy showing a sustained virologic response (SVR) rate of 80-90% with minimal adverse events, hepatitis C virus (HCV) eradication is a realistic goal of treatment. Therefore, a screening strategy for HCV-infected populations according to each country's epidemiology and disease burden is required.